Skip Navigation LinksHome > February 2011 - Volume 52 - Issue 2 > Guidance for Clinical Trials for Children and Adolescents Wi...
Journal of Pediatric Gastroenterology & Nutrition:
doi: 10.1097/MPG.0b013e3181f6f09c
Clinical Guideline

Guidance for Clinical Trials for Children and Adolescents With Chronic Hepatitis C

Wirth, Stefan*; Kelly, Deirdre; Sokal, Etienne; Socha, Piotr§; Mieli-Vergani, Giorgina||; Dhawan, Anil||; Lacaille, Florence; Raymond, Agnès Saint#; Olivier, Sophie#; Taminiau, Jan#

Collapse Box


Most children with chronic hepatitis C are infected vertically, have a low natural seroconversion rate, and carry a lifetime risk of cirrhosis and cancer. Affected children are usually asymptomatic, and histological findings are mild with a low risk of progression, although 5% develop significant liver disease in childhood.

The use of combination treatment with pegylated interferon-α and ribavirin has changed the outcome and prognosis for this disease, with approximately 60% of children achieving sustained viral clearance. Combination therapy is not ideal for children because pegylated interferon is administered subcutaneously, impairs growth velocity, and both interferon and ribavirin have significant adverse effects that affect compliance. In addition, approximately 50% of children infected with genotype 1 do not respond to therapy. Thus, additional treatment options are required including improvement in dosing, reduction in the length of treatment, and evaluation of new drugs, such as protease inhibitors, which could be more effective for patients infected with genotype 1.

The primary goal of treatment is to eradicate the infection. The future clinical trial design should ensure that any new drugs demonstrate noninferiority to the present standard regimen in both children and adults. The measure for documenting substantial improvement above present therapy should be increased viral clearance rate or the same clearance rate, with a shorter duration of treatment and/or fewer adverse effects. We do not believe there is any need for a placebo arm because approved therapy is available and new treatments can be compared with present therapy.

Safety measures should include the standard recommended laboratory investigations, growth parameters, quality-of-life or psychological measures, and a requirement for long-term follow-up for up to 5 years.

Copyright 2011 by ESPGHAN and NASPGHAN


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us